日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assay

OPTIMIZE 研究采用回顾性分析方法,利用 Abbott RealTime HCV RNA 检测技术,对接受特拉匹韦治疗的丙型肝炎病毒 (HCV) 感染患者进行管理。

Sarrazin, Christoph; Dierynck, Inge; Cloherty, Gavin; Ghys, Anne; Janssen, Katrien; Luo, Donghan; Witek, James; Buti, Maria; Picchio, Gaston; De Meyer, Sandra

Modeling viral evolutionary dynamics after telaprevir-based treatment

模拟特拉匹韦治疗后病毒的进化动力学

Haseltine, Eric L; De Meyer, Sandra; Dierynck, Inge; Bartels, Doug J; Ghys, Anne; Davis, Andrew; Zhang, Eileen Z; Tigges, Ann M; Spanks, Joan; Picchio, Gaston; Kieffer, Tara L; Sullivan, James C

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials

临床试验中接受以特拉瑞韦为基础的治疗的基因型 1 型初治患者和接受过治疗的患者中丙型肝炎病毒的演变

Tara L Kieffer, Sandra De Meyer, Doug J Bartels, James C Sullivan, Eileen Z Zhang, Ann Tigges, Inge Dierynck, Joan Spanks, Jennifer Dorrian, Min Jiang, Bambang Adiwijaya, Anne Ghys, Maria Beumont, Robert S Kauffman, Nathalie Adda, Ira M Jacobson, Kenneth E Sherman, Stefan Zeuzem, Ann D Kwong, Gaston

Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier

达芦那韦与人类免疫缺陷病毒 1 型蛋白酶的结合动力学解释了其强效的抗病毒活性和高遗传屏障

Inge Dierynck, Mieke De Wit, Emmanuel Gustin, Inge Keuleers, Johan Vandersmissen, Sabine Hallenberger, Kurt Hertogs